Reata Pharmaceuticals withdraws $86.3M stock offering
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Reata Pharmaceuticals Inc. is withdrawing a registration statement for the sale of up to $86.3 million worth of class A common shares.
The shelf registration was filed earlier this month and is being withdrawn due to "unfavorable market conditions."
